Irish-founded Shorla Oncology secures FDA approval for leukaemia drug

Shorla Oncology, an Irish-founded healthcare start-up that develops pharmaceutical therapies to help cancer patients, has secured FDA approval to bring a speciality drug designed to treat T-cell leukaemia, to market in the United States. The US Food and Drug Administration (FDA) has approved the use of the company’s oncology drug Nelarabine Injection for the treatment of leukaemia and lymphoblastic lymphoma.

Read more at: